Legal Representation
Attorney
Rosemary S. Tarlton
USPTO Deadlines
Application History
31 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 20, 2007 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Jun 20, 2007 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |
| Sep 20, 2006 | EEXT | I | TEAS EXTENSION RECEIVED |
| Sep 20, 2006 | EXT5 | S | EXTENSION 5 FILED |
| Sep 20, 2006 | EX5G | S | EXTENSION 5 GRANTED |
| Mar 22, 2006 | EEXT | I | TEAS EXTENSION RECEIVED |
| Mar 22, 2006 | EXT4 | S | EXTENSION 4 FILED |
| Mar 22, 2006 | EX4G | S | EXTENSION 4 GRANTED |
| Sep 14, 2005 | EEXT | I | TEAS EXTENSION RECEIVED |
| Sep 14, 2005 | EXT3 | S | EXTENSION 3 FILED |
| Sep 14, 2005 | EX3G | S | EXTENSION 3 GRANTED |
| Apr 5, 2005 | EEXT | I | TEAS EXTENSION RECEIVED |
| Apr 5, 2005 | EXT2 | S | EXTENSION 2 FILED |
| Apr 5, 2005 | EX2G | S | EXTENSION 2 GRANTED |
| Oct 4, 2004 | EX1G | S | EXTENSION 1 GRANTED |
| Sep 21, 2004 | EEXT | I | TEAS EXTENSION RECEIVED |
| Sep 21, 2004 | EXT1 | S | EXTENSION 1 FILED |
| Jun 23, 2004 | CFIT | O | CASE FILE IN TICRS |
| Apr 6, 2004 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT |
| Oct 6, 2003 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Aug 19, 2003 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jul 30, 2003 | NPUB | O | NOTICE OF PUBLICATION |
| Jun 19, 2003 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 14, 2003 | I | PAPER RECEIVED | |
| May 14, 2003 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 6, 2003 | CNFR | O | FINAL REFUSAL MAILED |
| Dec 11, 2002 | I | PAPER RECEIVED | |
| Dec 11, 2002 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jun 7, 2002 | CNRT | F | NON-FINAL ACTION MAILED |
| Jun 6, 2002 | DOCK | D | ASSIGNED TO EXAMINER |
| May 9, 2002 | DOCK | D | ASSIGNED TO EXAMINER |
Detailed Classifications
Class 005
Housemark for pharmaceutical components; pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular diseases, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular diseases, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; and anti-cancer vaccines
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"
USPTO Documents
Loading USPTO documents...